# Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab

> **NCT01867294** · PHASE2 · COMPLETED · sponsor: **Academic and Community Cancer Research United** · enrollment: 19 (actual)

## Conditions studied

- Advanced Malignant Neoplasm
- Dermatologic Complication

## Interventions

- **DRUG:** Doxycycline
- **PROCEDURE:** Management of Therapy Complications
- **OTHER:** Placebo
- **OTHER:** Questionnaire Administration
- **DRUG:** Spironolactone
- **DRUG:** Sunscreen
- **DRUG:** Therapeutic Hydrocortisone

## Key facts

- **NCT ID:** NCT01867294
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-31
- **Primary completion:** 2014-05-09
- **Final completion:** 2014-06-13
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01867294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01867294, "Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01867294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*